Clinical Trials Using Tetanus Toxoid Helper Peptide
Clinical trials are research studies that involve people. The clinical trials on this list are studying Tetanus Toxoid Helper Peptide. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
H3.3K27M-specific Peptide Vaccine and Poly ICLC with or without Nivolumab in Treating Patients with Newly Diagnosed HLA-A2 Positive, H3.3K27M Positive Diffuse Intrinsic Pontine Glioma or Other Newly Diagnosed Gliomas
This pilot phase I trial studies the side effects of H3.3K27M-specific peptide vaccine and how well it works with poly ICLC in treating patients with newly diagnosed HLA-A2 positive, H3.3K27M positive diffuse intrinsic pontine glioma or other newly diagnosed glioma including spinal cord tumors. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Poly ICLC may boost the immune system. Nivolumab is designed to target a specific marker on cancer cells. It is believed that when the marker is targeted, the immune system works better to attack tumor cells. Giving H3.3K27M-specific peptide vaccine and poly ICLC with or without nivolumab may work better at treating HLA-A2 positive, H3.3K27M positive glioma.
Location: 16 locations